Lexeo Therapeutics (LXEO) Interest Expenses (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Interest Expenses data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 417.82% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 70.16% YoY), and the FY2025 full-year result was $118.9 million, up 1790.26% from the prior year.
• Interest Expenses grew to $2.8 million in Q1 2026, from $542000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $18.2 million in Q1 2024 to a low of $40000.0 in Q4 2022.
• A 5-year average of $4.9 million and a median of $548000.0 in 2023 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses soared 3354.04% in 2024 and tumbled 97.08% in 2025, its largest moves.
• Tracing LXEO's Interest Expenses over 5 years: stood at $40000.0 in 2022, then rose by 25.0% to $50000.0 in 2023, then soared by 964.0% to $532000.0 in 2024, then grew by 1.88% to $542000.0 in 2025, then surged by 409.23% to $2.8 million in 2026.
• Business Quant data shows LXEO's Interest Expenses at $2.8 million in Q1 2026, $542000.0 in Q4 2025, and $8.7 million in Q3 2025.